Effect of Tolvaptan on polycystic liver and kidney is autosomal dominant polycystic kidney disease
Not Applicable
Recruiting
- Conditions
- ADPKD
- Registration Number
- JPRN-UMIN000016998
- Lead Sponsor
- Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1. The patient having a history of allergy to Tolvaptan or its analog. 2. The patient cannot feel thirsty or is unable to consume liquid. 3. The patient with hypernatremia. 4. The patient with severe renal function (less than eGFR 15mL/min/1.73m2). 5. The patient with chronic hepatitis or drug-induced liver injury of the history of these disease (except liver cysts). 6. The pregnant woman or the woman who has the possibility of the pregnancy. 7. The patient whom the primary doctor think not appropriate for participating the trial.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method